MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc. (Nasdaq: SEPR) today announced that the Centers for Medicare and Medicaid Services (CMS) has established a product-specific billing code, or J-code, for BROVANA® (arformoterol tartrate) Inhalation Solution under the Medicare Part B benefit. The J-code becomes effective on January 1, 2008. BROVANA is a long-term, twice-daily (morning and evening), maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. BROVANA is for use by nebulization only.
